Ir para o conteúdo principal

Collplant Biotechnologies (NASDAQ: CLGN) — Perfil da empresa, notícias e dados financeiros

Logo de Collplant Biotechnologies
CLGN Collplant Biotechnologies
Collplant Biotechnologies primary media
Perfil da empresa

Collplant Biotechnologies

Collplant Biotechnologies (NASDAQ:CLGN) specializes in regenerative and aesthetic medicine by leveraging its proprietary plant-based rhCollagen technology. This innovative approach aims at developing tissue repair products, bioinks for 3D bioprinting, and dermal fillers. Their groundbreaking projects include research into life-saving organs and skin regeneration treatments. The company's goal is to revolutionize medical treatments and improve patient outcomes through sustainable, scalable, and high-purity collagen production. Collplant is committed to expanding its portfolio of regenerative medicine products while focusing on strategic partnerships and technological advancements to meet the growing global demand.

Resumo

Public USParticipação acionária
2004Ano de fundação
73Funcionários
Rehovot, IsraelSede
Carregando mapa...
Presença global

Operações

Todos os locais
Reẖovot, IL

Produtos e/ou serviços de Collplant Biotechnologies

  • Development and commercialization of rhCollagen-based regenerative medical products for tissue repair and organ manufacturing.
  • Production of bioprinted tissues and organs utilizing proprietary recombinant human collagen (rhCollagen) technology.
  • Creation of VergenixSTR, an injectable gel for the treatment of tendinitis.
  • Development of VergenixFG, a flowable gel wound filler designed for the management of chronic wounds.
  • Innovation in aesthetic medicine through rhCollagen-based dermal fillers for cosmetic procedures.
  • Collaboration on research projects to explore the use of rhCollagen in various biomedical applications.

equipe executiva do Collplant Biotechnologies

  • Yehiel TalCEO & Chairman
  • Eran RotemDeputy CEO & CFO
  • Oren FahimipoorVice President of Operations
  • Oded ShoseyovFounder & Chief Scientist
  • Bar AbelisVice President of Legal
  • Hadas Dreiher HorowitzVice President of Human Resources

Principais indicadores financeiros

Resultados divulgados pela Collplant Biotechnologies, em USD.

Cap. de mercado
11,4 mi
Receita (TTM)
318 mil
P/L
—
LPA (diluído, TTM)
-9.6
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Collplant Biotechnologies
Fim do ano fiscalReceitaResultado operacionalLucro líquido
2,4 mi-11,5 mi-11,5 mi
515 mil-17,3 mi-16,6 mi
11 mi-7,5 mi-7 mi
299 mil-17,1 mi-16,9 mi